Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis

European Journal of Nutrition

Volumn 52, Issue 2, 2013, Pages 457-466

  Ocón, Borja ^a   Anzola, Andrea ^a   Ortega González, Mercedes ^a   Zarzuelo, Antonio ^a   Suárez, María D ^a   Sánchez De Medina, Fermín ^a   Martínez Augustin, Olga ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Active hexose correlated compound; Bifidobacterium longum BB536; Colitis; Symbiotic

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; MESSENGER RNA; MYELOPEROXIDASE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIFIDOBACTERIUM LONGUM; COLITIS; COLONIC WEIGHT TO LENGTH RATIO; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; INTERLEUKIN 1BETA GENE; NONHUMAN; ORGAN WEIGHT; PROTEIN EXPRESSION; RAT; WEIGHT GAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIFIDOBACTERIUM; BLOTTING, WESTERN; COLITIS; COLON; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-2; NITRIC OXIDE SYNTHASE TYPE II; ORGAN SIZE; POLYSACCHARIDES; PREBIOTICS; PROBIOTICS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

BASIDIOMYCOTA; BIFIDOBACTERIUM LONGUM; RATTUS;

EID: 84879551958     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-012-0347-z     Document Type: Article

References (16)

1. Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl J Med 361:2066-2078. doi: 10.1056/NEJMra0804647
2. Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241-259. doi: 10.1194/jlr.R500013- JLR200
3. Williams NT (2010) Probiotics. Am J Health Syst Pharm 67:449-458. doi: 10.2146/ajhp090168
4. Preidis GA, Versalovic J (2009) Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136:2015-2031. doi: 10.1053/j.gastro.2009.01. 072
5. Miura T, Kitadate K, Nishioka H, Wakame K (2010) Basic and clinical studies on active hexose correlated compound. In: Bagchi D, Lau FC, Ghosh DK (eds) Biotechnology in functional foods and nutraceuticals. CRC Press, Boca Raton, pp 51-59
6. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, Requena P, Zarzuelo A, Suarez MD, de Medina FS, Martinez-Augustin O (2007) Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr 137:1222-1228
7. Martínez-Augustin O, López-Posadas R, González R, Suárez MD, Zarzuelo A, Sánchez de Medina F (2009) Genomic analysis of sulfasalazine effect in experimental colitis is consistent primarily with modulation of NF-kB but not PPAR-g signaling. Pharmacogenet Genomics 19:363-372
8. Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344-1350
9. Lopez-Posadas R, Gonzalez R, Ballester I, Martinez-Moya P, Romero-Calvo I, Suarez MD, Zarzuelo A, Martinez-Augustin O, Sanchez de Medina F (2011) Tissue-nonspecific alkaline phosphatase is activated in enterocytes by oxidative stress via changes in glycosylation. Inflamm Bowel Dis 17:543-556. doi: 10.1002/ibd.21381
10. Lee B, Lee JH, Lee HS, Bae EA, Huh CS, Ahn YT, Kim DH (2009) Glycosaminoglycan degradation-inhibitory lactic acid bacteria ameliorate 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. J Microbiol Biotechnol 19:616-621. doi: 10.4014/jmb.0808.479
11. Roselli M, Finamore A, Nuccitelli S, Carnevali P, Brigidi P, Vitali B, Nobili F, Rami R, Garaguso I, Mengheri E (2009) Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis 15:1526-1536. doi: 10.1002/ibd.20961
12. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10:PI126-PI131
13. Bai AP, Ouyang Q, Xiao XR, Li SF (2006) Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 60:284-288. doi: 10.1111/j.1368-5031.2006.00833.x
14. Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME (2009) Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents 34:197.e1-197.e10. doi: 10.1016/j.ijantimicag. 2008.11.005
15. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C (2009) A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 25:520-525. doi: 10.1016/j.nut.2008.11.017
16. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT (2005) Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:242-249. doi: 10.1136/gut.2004. 044834